In the landscape of modern drug discovery, the traditional laboratory workflow is undergoing a seismic shift. For decades, the path of a tissue slide was linear and finite: a pathologist would examine a specimen, document the findings in a report, and file the glass slide away in a physical archive. Today, that "one-way street" is being transformed into a vast, high-definition data repository, thanks to the maturation of digital pathology. By digitizing these samples and applying advanced computational analysis, researchers are uncovering molecular insights that were previously inaccessible, effectively mining the past to spare the future.
This transition is more than a technical upgrade; it is a fundamental rethinking of how we conduct preclinical animal research. As the industry faces mounting pressure to reduce animal dependency, the ability to extract greater value from existing tissue samples and historical data is emerging as a cornerstone of the "New Approach Methodologies" (NAMs) movement.
The Evolution of the Digital Slide
The catalyst for this transformation was the COVID-19 pandemic, which forced a rapid, necessity-driven adoption of digital pathology. When lockdowns prevented pathologists from accessing physical microscopes, the digitization of slides—previously a niche interest—became an operational lifeline.
However, what began as a remote work solution has evolved into a powerful scientific asset. "Before, the pathology endpoint was just a report," explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. "Now you have the digitized slide, which is pixels."
These pixels represent a trove of biological data. By integrating digital images with molecular measurements and historical pathology reports, researchers are training artificial intelligence models to recognize patterns that correlate with complex molecular changes. A single slide, once viewed only for its diagnostic utility, is now a multi-dimensional data source capable of answering questions that were not even contemplated when the original study was conducted.
Chronology: From Glass Archives to Digital Intelligence
- Pre-2020: The era of "analog pathology." Slides were viewed under physical microscopes and stored in physical archives. Research was limited to the initial intent of the study.
- 2020–2022: The "Digital Shift." Pandemic-induced restrictions accelerated the adoption of whole-slide imaging (WSI) and remote diagnostic platforms.
- 2022: The passage of the FDA Modernization Act 2.0, which signaled a legislative shift toward accepting non-animal methods for regulatory submissions.
- 2024: Charles River Laboratories launched its "Alternative Methods Advancement Project," focusing on virtual control groups and the repurposing of historical data.
- 2025: New guidance from the Organisation for Economic Co-operation and Development (OECD) provided a framework for using preserved tissue for advanced "omics" analysis.
- 2026: The FDA published updated regulatory guidance and a roadmap for reducing animal testing, positioning NAMs as the future default for preclinical safety assessments.
Supporting Data: The Power of Virtual Controls
One of the most immediate impacts of this data-driven approach is the implementation of "virtual control groups." In traditional toxicology studies, a significant number of animals must be used as concurrent controls to ensure that observed drug effects are genuine. By aggregating and validating vast sets of historical data, researchers can now create "virtual" baselines that are statistically robust.
"Control animals are always a big fraction of every study," Dr. Zuraw notes. "Replacing some of them with matched historical data cuts animal numbers by simple arithmetic."
The challenge lies in ensuring that historical data is sufficiently comparable to current study conditions. Charles River’s specialized teams are currently dedicated to curating these datasets, ensuring that the biological context is preserved so that researchers can confidently distinguish between a drug-induced effect and background biological variability. This methodology effectively allows for the same, if not higher, level of statistical certainty with fewer physical subjects.
Preserving the Context: The Role of FFPE Blocks
When a toxicology study concludes, tissues are typically fixed in formalin and embedded in paraffin wax (FFPE). These blocks are often treated as permanent records of the study. Previously, extracting molecular information from these blocks required significant foresight and planning—usually before the study even began.
However, modern techniques are changing the value of these archives. The 2025 OECD guidance on "omics" analysis has provided a standardized path for researchers to extract genetic and protein-level data from these stored samples.
"Now you have the option to use FFPE material that was already part of a lot of studies for additional information," says Dr. Zuraw. "You don’t lose the context of the study." By cross-referencing molecular findings from archived tissue with original dosing records and control data, scientists can perform secondary investigations without the need to initiate new, resource-intensive animal experiments.
Regulatory Implications and the Shift in Standards
The regulatory landscape has moved in lockstep with these technical advancements. The FDA’s push to move away from animal testing as the "gold standard" is a major driver of this innovation. The agency’s 2025 roadmap, which outlines a transition from monoclonal antibodies to broader chemical entities, is setting a clear trajectory for the pharmaceutical industry: over the next three to five years, animal studies are expected to become the exception, while NAMs become the expected norm.
This shift necessitates a new culture of transparency and collaboration. Dr. Zuraw emphasizes that for these methods to be accepted, early adopters must pave the way. "You still need enough early adopters to generate precedent," she explains. "Those early adopters will embrace the guidance, figure it out and troubleshoot, and then others can build on their work without reinventing the wheel."
Cutting-Edge Horizons: Virtual Staining
Beyond repurposing existing slides, the field is pushing into "virtual staining"—an innovation that may eventually render traditional glass slides obsolete. In this process, a scanner captures an unstained tissue section, and specialized software uses AI to generate the visual representation of a stain.
This is more than a novelty; it is a leap toward standardized, high-throughput digital workflows. By skipping the physical staining process, laboratories reduce the risk of chemical degradation and human error, while simultaneously creating a digital-first environment that is natively compatible with machine learning analysis.
Conclusion: A Snowball Effect for Drug Discovery
The transition toward digital pathology is not just about adopting new software; it is about changing the mindset of an entire industry. We are moving toward a future where every experiment serves as a permanent, searchable, and re-analyzable asset.
As more laboratories invest in the infrastructure to share and analyze these digital assets, the field is poised to reach a tipping point. Dr. Zuraw describes this as a potential "snowball effect." By opening up data sources that were previously locked in physical archives, the scientific community is gaining the ability to conduct more rigorous, humane, and cost-effective research.
Ultimately, the power to mine old tissue for new insights offers a dual benefit: it accelerates the pace of drug discovery while significantly reducing the reliance on animal models. As these technologies mature, they will not only change how we look at tissue—they will change the very definition of what a study can achieve, turning past research into the foundational knowledge that builds the medicines of tomorrow.
About the Author
